Table 3 12-month follow-up

Total Participants (N)

23

12

13

Gender (female, %)

26

25

46

0.397

Age (years)

47.2 ± 13.6

49.9 ± 14.9

48.8 ± 12.7

0.843

Caucasian (%)

70

42

77

0.167

Diabetes (%)

22

30

15

0.802

Stroke (%)

0

10

0

0.222

Congestive Heart Failure (%)

4

10

0

0.466

Currently smoking (%)

26

0

15

0.429

Beck Depression Index

11.9 ± 10.2

8.8 ± 5.9

7.7 ± 6.2

0.322

Modified Mini-Mental Status

89.4 ± 4.9

90.3 ± 4.7

89.8 ± 4.3

0.877

Weekly Std Kt/V

2.27 ± 0.21

5.56 ± 1.15

NA

0.001*

Pre Dialysis BUN (mg/dL)

61 ± 17

43 ± 14

NA

0.008*

Pre Dialysis Creatinine (mg/dL)

10.1 ± 2.8

7.1 ± 3.1

1.5 ± 0.6

0.001*

Pre Dialysis Albumin (g/dL)

4.1 ± 0.5

4.0 ± 0.4

4.5 ± 0.4

0.136

Pre Dialysis Phosphorus (mg/dL)

5.8 ± 1.6

4.3 ± 1.6

2.7 ± 0.4

0.001*

Hemoglobin (g/dL)

11.9 ± 1.5

11.3 ± 2.1

13.8 ± 1.2

0.001*

Pre Dialysis Systolic Blood Pressure (mmHg)

149 ± 26

135 ± 17

NA

0.123

Pre Dialysis Diastolic Blood Pressure (mmHg)

84 ± 12

76 ± 12

NA

0.098

Ultra Filtration Volume (L)

2.9 ± 1.4

2.2 ± 1.0

NA

0.179

Urea Reduction Ratio (%)

73 ± 8

78 ± 14

NA

0.158

Vitamin D use (%)

27

17

23

0.905

Medication

 H1 Receptors (%)

13

8

8

1.000

 Narcotic (%)

39

25

23

0.561

 Muscle Relaxant (%)

0

8

0

0.250

 Anti-Depressant (%)

39

33

31

0.926

 Sedative-hypnotic (%)

17

0

0

0.170

 Anxiolytic (%)

13

8

8

1.000

 Patient Hospitalized (%)

30

42

15

0.357